Recursion Pharmaceuticals

RXRX

Market cap $1.98B

Recursion Pharmaceuticals (RXRX) closed at $3.32 in the latest trading session, marking a -2.06% move from the prior day.

Salt Lake City, April 07, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following upcoming investor conferences: 25th Annual Needham Virtual Healthcare Conference - Monday, April 13, 2026 Bank of America Health Care Conference 2026 - Tuesday, May 12, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com . About Recursion Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives.

Recursion Pharmaceuticals (RXRX) reached $3.11 at the closing of the latest trading day, reflecting a +1.63% change compared to its last close.

Alphabet is already a leader in AI and boasts attractive growth avenues beyond this industry. Recursion Pharmaceuticals has a long way to go before demonstrating that its approach works.

Citeline, a leader in clinical solutions for the life sciences, announced an expanded strategic partnership with Recursion, a leading tech-bio company.

AI-powered drug discovery and development is now a possibility. Artificial intelligence is also able to help caregivers navigate a complex collection of ever-changing treatment options.

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $2.94, representing a -6.67% change from its previous close.

Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?

Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion's Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role.

Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor can build from scratch.